Company intelligence / Profile preview

Liang Fang Pharmaceutical

Beijing, China

Ownership: Private
Development stage: Other

Overview

Liang Fang Pharmaceutical, as part of Lotus, sells and distributes more than 8,000 products in China—several are marketed and others are in preclinical or regulatory approval phases[2][9][10][6][8]. Pipeline includes treatments for cardiovascular diseases, diabetes, asthma, and various other indications.

Therapeutic areas: OtherEndocrinologyCardiovascularDermatologyInfectious DiseasesPulmonologyGastroenterologyMen's Health
Modalities: Small moleculeTraditional Chinese medicine
Industry: Biotech

Beyond the preview

Go deeper on Liang Fang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liang Fang Pharmaceutical.

Explore the full profile